Haemophilia B, also known as Christmas disease, is a genetic bleeding disorder caused by a deficiency of clotting factor IX. Here are the answers to your questions:
Haemophilia B: Haemophilia B is a subtype of haemophilia, which is characterized by the deficiency or dysfunction of clotting factor IX, a protein involved in the blood clotting process. It is an inherited disorder that primarily affects males, although females can be carriers of the condition.
Christmas disease: Haemophilia B is also referred to as Christmas disease because it was named after Stephen Christmas, the first patient diagnosed with this particular subtype. Christmas, a patient in the 1950s, was identified as having a deficiency of clotting factor IX during the Christmas season, hence the name.
Causes of haemophilia B: Haemophilia B is caused by an inherited genetic mutation in the gene responsible for producing clotting factor IX. This mutation leads to reduced or absent production of factor IX, resulting in impaired blood clotting ability.
Effects of haemophilia B: Individuals with haemophilia B experience prolonged bleeding and delayed clotting after injuries or surgeries. They are more prone to spontaneous bleeding into joints, muscles, and other internal organs. Common symptoms include frequent and prolonged nosebleeds, easy bruising, joint pain and swelling, prolonged bleeding from cuts, and, in severe cases, spontaneous internal bleeding.
Treatment for haemophilia B involves replacing the missing clotting factor IX through regular infusions of factor IX concentrates or recombinant factor IX. This helps restore the clotting ability and prevents excessive bleeding. Individuals with haemophilia B also need to take precautions to avoid injury and manage bleeding episodes promptly.
It's important for individuals with haemophilia B to work closely with a medical team specializing in haemophilia care to develop a personalized treatment plan and receive regular monitoring to prevent complications and manage their condition effectively.
Difference between Haemophilia A and haemophilia B
Haemophilia A and haemophilia B are two different subtypes of haemophilia, which are inherited bleeding disorders. Here are the differences between the two:
Clotting Factor Deficiency: The main difference between haemophilia A and haemophilia B lies in the specific clotting factor that is deficient in each subtype.
Haemophilia A: In haemophilia A, there is a deficiency or absence of clotting factor VIII, which is necessary for the blood to form stable clots.
Haemophilia B: In haemophilia B, also known as Christmas disease, there is a deficiency or absence of clotting factor IX, which is involved in the blood clotting cascade.
Prevalence: Haemophilia A is more common than haemophilia B. It accounts for about 80-85% of all cases of haemophilia, while haemophilia B accounts for the remaining 15-20%.
Inheritance: Both haemophilia A and haemophilia B are inherited disorders that follow an X-linked recessive pattern. This means that the faulty gene responsible for the condition is located on the X chromosome. As a result, haemophilia is typically seen in males, who inherit the affected X chromosome from their carrier mother. Females can be carriers of the gene but are generally unaffected unless they inherit the faulty gene from both parents.
Severity: The severity of haemophilia can vary among individuals, regardless of whether it is haemophilia A or haemophilia B. Both subtypes can range from mild to severe, depending on the amount of clotting factor present in the blood. Severe cases of haemophilia have less than 1% of the normal clotting factor level, while mild cases have between 5-40% of the normal level.
Treatment: The treatment approaches for haemophilia A and haemophilia B are similar and involve replacing the deficient clotting factor. This is achieved through the administration of clotting factor concentrates, either derived from human blood plasma or produced through recombinant DNA technology. The goal is to restore the missing clotting factor and prevent or manage bleeding episodes effectively.
It's important for individuals with haemophilia, whether haemophilia A or haemophilia B, to work closely with their healthcare team to develop a comprehensive treatment plan, which may include regular factor replacement therapy, prophylactic treatment, and preventive measures to minimize the risk of bleeding complications.
What did you think of this article?
We value your feedback and would love to hear your thoughts on this article.
Write to: hello [at] watchdoq [dot] com with questions or comments.
Additional Resources